v3.26.1
Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Profit or loss [abstract]        
Revenues $ 5,229 $ 16,725 $ 11,006 $ 27,380
Other income 1,675 1,469 3,446 2,842
Total revenues and other income 6,904 18,193 14,452 30,222
Operating expenses        
Research and development expenses (24,976) (23,080) (52,165) (45,012)
Selling, general and administrative expenses (5,739) (5,078) (11,329) (9,780)
Other operating income 290 378 353 804
Total operating expenses and other operating income (30,425) (27,779) (63,140) (53,988)
Operating loss (23,521) (9,586) (48,688) (23,766)
Financial income 4,739 5,545 16,568 11,578
Financial expenses (3,011) (19,695) (7,392) (29,675)
Net Financial gain (loss) 1,727 (14,150) 9,176 (18,098)
Income tax (25) 0 (72) 0
Net income (loss) $ (21,819) $ (23,736) $ (39,584) $ (41,863)
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis        
Basic net income (loss) attributable to shareholders of Cellectis, per share ($ /share) $ (0.22) $ (0.24) $ (0.39) $ (0.42)
Diluted net income (loss) attributable to shareholders of Cellectis, per share ($ /share) $ (0.22) $ (0.24) $ (0.39) $ (0.42)
Number of shares used for computing        
Basic 100,647,451 100,305,204 100,587,696 100,231,292
Diluted 100,647,451 100,305,204 100,587,696 100,231,292